Share on StockTwits

Achillion Pharmaceuticals (NASDAQ:ACHN) Director Michael D. Kishbauch sold 495,812 shares of Achillion Pharmaceuticals stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $9.40, for a total value of $4,660,632.80. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

ACHN has been the subject of a number of recent research reports. Analysts at Maxim Group reiterated a “buy” rating on shares of Achillion Pharmaceuticals in a research note on Friday. Separately, analysts at FBR Capital Markets initiated coverage on shares of Achillion Pharmaceuticals in a research note on Friday. They set an “outperform” rating and a $12.00 price target on the stock. Finally, analysts at Piper Jaffray upgraded shares of Achillion Pharmaceuticals from a “neutral” rating to an “overweight” rating in a research note on Monday, August 11th. They now have a $10.00 price target on the stock, up previously from $5.00. One analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the stock. Achillion Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $7.80.

Achillion Pharmaceuticals (NASDAQ:ACHN) traded up 9.60% during mid-day trading on Friday, hitting $9.25. The stock had a trading volume of 21,933,368 shares. Achillion Pharmaceuticals has a 52 week low of $2.26 and a 52 week high of $9.94. The stock has a 50-day moving average of $7.3 and a 200-day moving average of $4.58. The company’s market cap is $904.5 million.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.18) by $0.02. Analysts expect that Achillion Pharmaceuticals will post $-0.73 EPS for the current fiscal year.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.